Polyvalent Carbohydrate-based Vaccine Development

Polyvalent Carbohydrate-based Vaccine Development

Polyvalent glycoconjugates with natural or unnatural carbohydrate antigen epitopes have the potential as vaccines to stimulate innate and adaptive immune responses. CD BioGlyco is committed to designing and synthesizing polyvalent glycoconjugates with optimal ligand density and appropriate linkers to provide customers with multivalent carbohydrate vaccine development services.

Polyvalent Carbohydrate-based Vaccine

During the first step of infection, pathogens adhere to host cells through multivalent interactions involving protein-glycan recognition. Individual interactions between carbohydrates and proteins are weak, but multiple simultaneous interactions result in strong functionally useful affinities. Currently, the development of polyvalent vaccines based on glycoconjugates has been fruitful, and many carbohydrate-based vaccines against various bacterial infections are available or in clinical trials, such as vaccines against Streptococcus pneumoniae, Shigella dysenteriae, Haemophilus influenzae, and Neisseria meningitides.

In the development of carbohydrate-based anticancer vaccines, researchers have found that single-molecule pentavalent vaccines combining multiple carbohydrate antigens and carrier protein couples could mimic immune responses against heterogeneous carbohydrate epitopes expressed on the surface of cancer cells. Compared to combined monomeric vaccines, single-molecule pentavalent vaccines allow for higher yields of the final conjugation step, simplified carbohydrate ratio validation steps, simulated cancer cell heterogeneity, and lower amounts of carrier proteins to minimize immunosuppression.

 Fig. 1 Unimolecular pentavalent vaccine containing Globo H, STn, Tn, LeY or GM2 and TF.Fig.1 Unimolecular pentavalent vaccine containing Globo H, STn, Tn, LeY or GM2 and TF. (Mettu, 2020)

Our Services

To increase vaccination rates and reduce the number of vaccinations, CD BioGlyco has established an advanced and specialized platform to help our clients develop polyvalent carbohydrate vaccines. The services we provide include but are not limited to:

  • Development of polyvalent glycoconjugate vaccines against different pathogens. We have the ability to prepare conjugates with different saccharide densities of tetra-, octa-, dodeca-, and hexadecasaccharides for the development of multivalent vaccines against different pathogens.
  • Development of polyvalent carbohydrate-based HIV vaccines.
  • Development of polyvalent vaccines against cancer. We have successfully prepared pentavalent and hexavalent carbohydrate antigenic constructs on a single peptide skeleton, conjugated with keyhole limpet hemocyanin (KLH) and Pam3Cys.


  • Research on anti-infectious and anti-inflammatory drug candidates
  • Exploration of more effective carbohydrate-based vaccines
  • Prevention of various parasitic infections

Advantages of Us

  • Advanced technology and methods
  • World-class experimental platform
  • Good reputation and credibility
  • Customer-centered services

With advanced experimental platforms and professional research teams, CD BioGlyco provides customers with the optimal solutions in the field of carbohydrate-based polyvalent vaccine development. We have established continuous cooperative relations with our customers all over the world. If you need our assistance, please feel free to contact us.


  1. Bhatia, S. et al. Multivalent glycoconjugates as vaccines and potential drug candidates. Med.chem.commun. 2014, 5(7):862-878.
  2. Mettu, R. et al. Synthetic carbohydrate-based vaccines: challenges and opportunities. Journal of Biomedical Science. 2020, 27(1):1-22.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.